Pralidoxime
Duodote, Protopam (pralidoxime) is a small molecule pharmaceutical. Pralidoxime was first approved as Protopam chloride on 1982-01-01. It is used to treat drug overdose and poisoning in the USA. The pharmaceutical is active against acetylcholinesterase.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| chemically-induced disorders | D064419 |
| mental disorders | D001523 |
Trade Name
FDA
EMA
Protopam (discontinued: Pralidoxime, Protopam)
CombinationsDuodote (discontinued: Atnaa)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Pralidoxime chloride
Atropine
+
Pralidoxime chloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DUODOTE | Meridian Medical Technologies | N-021983 RX | 2006-09-28 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| antibacterial | OTC monograph not final | 2010-08-24 |
| antibacterial hand sanitizer | OTC monograph not final | 2010-10-08 |
| atnaa | 2007-05-17 | |
| atnaa atropine and pralidoxime chloride | New Drug Application | 2022-07-18 |
| backaid | C200263 | 2025-04-14 |
| caso candiq. plus | unapproved drug other | 2017-07-19 |
| caso hair vita | unapproved drug other | 2017-07-19 |
| caso skin vita | unapproved drug other | 2017-07-19 |
| cramp tabs | C200263 | 2024-10-04 |
| cvs pinworm treatment | C200263 | 2024-12-18 |
Show 44 more
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J2730 | Injection, pralidoxime chloride, up to 1 gm |
Clinical
Clinical Trials
191 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | 1 | 1 | 2 |
| Coronary artery bypass | D001026 | EFO_0003776 | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | — | C90.0 | 14 | 25 | 4 | — | 2 | 39 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 11 | 14 | 1 | — | 2 | 26 |
| Myelodysplastic syndromes | D009190 | — | D46 | 10 | 14 | 1 | — | 1 | 24 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 8 | 12 | 1 | — | 3 | 23 |
| Plasma cell neoplasms | D054219 | — | — | 2 | 9 | 2 | — | 1 | 14 |
| Lymphoma | D008223 | — | C85.9 | 4 | 7 | 1 | — | 3 | 14 |
| Neuroblastoma | D009447 | EFO_0000621 | — | 6 | 4 | 3 | — | 1 | 14 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 5 | 6 | 1 | — | 3 | 13 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 5 | 1 | — | 2 | 9 |
| Melanoma | D008545 | — | — | 3 | 2 | 1 | — | 3 | 8 |
Show 12 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 13 | 19 | — | — | 3 | 28 |
| Hodgkin disease | D006689 | — | C81 | 8 | 10 | — | — | 3 | 18 |
| Leukemia | D007938 | — | C95 | 4 | 9 | — | — | 2 | 14 |
| Myeloproliferative disorders | D009196 | — | D47.1 | 6 | 6 | — | — | 1 | 13 |
| Mantle-cell lymphoma | D020522 | — | C83.1 | 5 | 8 | — | — | 3 | 12 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 4 | 7 | — | — | 3 | 12 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 3 | 8 | — | — | 1 | 10 |
| Follicular lymphoma | D008224 | — | C82 | 3 | 7 | — | — | 3 | 10 |
| Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 2 | 7 | — | — | 1 | 10 |
| Primary myelofibrosis | D055728 | — | D47.4 | 3 | 6 | — | — | 1 | 10 |
Show 108 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ewing sarcoma | D012512 | EFO_0000173 | — | 3 | — | — | — | 2 | 5 |
| Sarcoma | D012509 | — | — | 1 | — | — | — | 3 | 4 |
| Myeloid leukemia | D007951 | — | C92 | 2 | — | — | — | 1 | 3 |
| Poisoning | D011041 | EFO_0008546 | T65.91 | 1 | — | — | — | 2 | 3 |
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | 1 | 3 |
| Rhabdoid tumor | D018335 | — | — | 2 | — | — | — | — | 2 |
| Ependymoma | D004806 | — | — | 2 | — | — | — | — | 2 |
| Preleukemia | D011289 | — | — | 2 | — | — | — | — | 2 |
| Wilms tumor | D009396 | EFO_0000212 | — | 2 | — | — | — | — | 2 |
| Testicular neoplasms | D013736 | — | C62 | 1 | — | — | — | 1 | 2 |
Show 19 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Exercise | D015444 | EFO_0000483 | — | — | — | — | — | 3 | 3 |
| Intraocular lymphoma | D064090 | — | — | — | — | — | — | 2 | 2 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | — | — | 2 | 2 |
| Infections | D007239 | EFO_0000544 | — | — | — | — | — | 2 | 2 |
| Diabetic foot | D017719 | EFO_1001459 | — | — | — | — | — | 2 | 2 |
| Chronic renal insufficiency | D051436 | — | N18 | — | — | — | — | 2 | 2 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | — | — | 2 | 2 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | — | 2 | 2 |
| Septic shock | D012772 | — | A48.3 | — | — | — | — | 2 | 2 |
| Shock | D012769 | — | R57.1 | — | — | — | — | 2 | 2 |
Show 65 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Pralidoxime |
| INN | — |
| Description | Pralidoxime is a pyridinium ion that is 1-methylpyridinium substituted by a (hydroxyimino)methyl group at position 2. It has a role as a cholinergic drug, a cholinesterase reactivator, an antidote to organophosphate poisoning and an antidote to sarin poisoning. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[n+]1ccccc1C=NO |
Identifiers
| PDB | — |
| CAS-ID | 6735-59-7 |
| RxCUI | 1546365 |
| ChEMBL ID | CHEMBL1420 |
| ChEBI ID | 8354 |
| PubChem CID | 135398747 |
| DrugBank | DB00733 |
| UNII ID | — |
Target
Agency Approved
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Zyprexa – Eli Lilly
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 68,021 documents
View more details
Safety
Black-box Warning
Black-box warning for: Imipramine pamoate, Pamelor, Zyprexa
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
222,357 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use